Related Experiment Video
Updated: May 10, 2026
04:24
An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
Published on: June 16, 2023
PiHelper: an open source framework for drug-target and antibody-target data
Bülent Arman Aksoy1, Jianjiong Gao, Gideon Dresdner
1Computational Biology Center, Memorial Sloan-Kettering Cancer Center, NY 10065, USA. pihelper@cbio.mskcc.org
Bioinformatics (Oxford, England)
|June 15, 2013
Summary
PiHelper integrates drug-target and antibody-target data into a single resource. This user-friendly framework aids researchers in systems pharmacology and proteomics by providing tools for data access, searching, and visualization.
Area of Science:
- Biochemistry
- Pharmacology
- Proteomics
Background:
- Drug-target and antibody-target interactions are crucial for therapeutic interventions.
- Existing databases for drug-target and antibody-target data are not integrated.
- There is a need for a unified bioinformatics resource for accessing and querying this information.
Purpose of the Study:
- To develop an integrated bioinformatics resource for drug-target and antibody-target associations.
- To provide researchers with a user-friendly toolset for accessing and querying this data.
- To support research in systems pharmacology, perturbation biology, and proteomics.
Main Methods:
- Integration of human drug-target and antibody-target associations from public resources.
- Development of a framework named PiHelper.
- Implementation of utilities for data import, programmatic and web-based searching, interactive network visualization, and data export.
Main Results:
- The PiHelper framework successfully integrates diverse drug-target and antibody-target data.
- PiHelper offers functionalities for comprehensive data exploration and analysis.
- The framework includes tools for programmatic and web-based querying, network visualization, and data export.
Conclusions:
- PiHelper provides an integrated solution for drug-target and antibody-target associations.
- The framework meets the needs of researchers in systems pharmacology, perturbation biology, and proteomics.
- PiHelper is available as free software with source code and documentation, encouraging community contributions.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...